Purchase Represents 43 Percent Premium
Ceradyne accepted a purchase price of $35 a share from 3M. CRDN, which closed at $24.43 on Friday, surges 43 percent before the bell on my tradeMONSTER platform.
Exelixis Reports Positive Interim Data
Exelixis reported that 40 milligram doses of its cabozantinib drug appear to have similar results as larger doses in reducing metastatic bone and soft tissue disease. The preliminary data based on phase II trials was released over the weekend. EXEL climbs 4 percent in early trading.
Apricus Climbs on Canadian Marketing Intent
Apricus Biosciences announced its intent to file a New Drug Submission in Canada for MycoVa, the company's topical treatment for onychomycosis. APRI is up 7 percent in the premarket.
Ariad Pharma Climbs on Cancer Trial Results
Ariad Pharmaceuticals reported positive initial clinical results for AP26113, an investigational compound for the treatment of non-small cell lung cancer. ARIA, already up 98 percent his year, climbs another 4 percent in the pre.
More From optionMONSTER